BioSpace10h
GLP-1 Prescriptions for Type 1 Diabetes Spike Despite Lack of FDA Approval: Study
While the regulator has not approved their use in type 1 diabetes, off-label prescribing for GLP-1 receptor agonists has ...
FiercePharma1d
Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutide
In the middle is the FDA trying to referee the high-stakes and increasingly ... copycat versions of its juggernaut diabetes ...
Becker's Hospital Review1d
Novo Nordisk to FDA: Ozempic, Wegovy too complex to be copied
Novo Nordisk has requested that the FDA prohibit compounding pharmacies from producing unapproved versions of its popular weight loss and diabetes drugs, Wegovy and Ozempic, CNBC reported Oct. 23.
Benefits Pro6d
Can the FDA just use 'march-in rights' to make its own Wegovy?
The "takings clause" in the Fifth Amendment to the U.S. Constitution might keep the federal government from creating ...
FDA says this weight loss drug shortage is over, but patients worry about cost and availability
Some patients fear tirzepatide, sold by Eli Lilly under the brand names Zepbound and Mounjaro, will be hard to get and prohibitively expensive once compounding pharmacies are no longer producing it.
Amid backlash, FDA changes course over shortage of weight-loss drugs
The FDA said Eli Lilly’s weight-loss drugs were no longer in shortage on Oct. 2, preventing pharmacies from making cheaper ...